Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vir Biotechnology, Inc. VIR
$24.41
+$0.16 (0.66%)
На 18:02, 12 мая 2023
+43.38%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3261219850.00000000
-
week52high
31.78
-
week52low
18.05
-
Revenue
1580472000
-
P/E TTM
6
-
Beta
0.25435900
-
EPS
3.94000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 20:00
Описание компании
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 мая 2022 г. |
| Needham | Buy | Buy | 06 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 30 мар 2022 г. |
| Needham | Buy | Buy | 28 мар 2022 г. |
| Baird | Neutral | Underperform | 03 мар 2022 г. |
| SVB Leerink | Outperform | 14 сент 2022 г. | |
| Morgan Stanley | Underweight | 09 сент 2022 г. | |
| SVB Leerink | Outperform | Outperform | 04 ноя 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| Morgan Stanley | Underweight | Underweight | 04 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 27 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Underweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | D | 19045064 | 86801 | 02 февр 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19131865 | 35173 | 01 февр 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19167038 | 26661 | 01 февр 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19193699 | 70567 | 31 янв 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19264266 | 3316 | 31 янв 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19267582 | 11904 | 30 янв 2023 г. |
| SVF Endurance (Cayman) Ltd | D | 19279486 | 67026 | 30 янв 2023 г. |
| Pang Phillip | D | 37535 | 4594 | 24 янв 2023 г. |
| Pang Phillip | D | 13576 | 25406 | 24 янв 2023 г. |
| Pang Phillip | D | 144000 | 30000 | 24 янв 2023 г. |
Новостная лента
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
InvestorPlace
02 февр 2023 г. в 14:19
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
Zacks Investment Research
01 февр 2023 г. в 12:02
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
Zacks Investment Research
24 янв 2023 г. в 13:33
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Stocks That Could Turn $100 Into $1,000 by 2028
The Motley Fool
22 янв 2023 г. в 07:15
These growth stocks have substantial tailwinds.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
20 янв 2023 г. в 11:17
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.